Enthesitis and dactylitis resolution with risankizumab for active psoriatic arthritis: Integrated analysis of the randomized KEEPsAKE 1 and 2 Trials

Kwatra et al. found that risankizumab significantly improves clinical signs and symptoms of enthesitis and/or dactylitis in PsA patients, with substantial and sustained efficacy observed up to 52 weeks. Furthermore, these improvements were met by meaningful gains in patient reported outcomes.

Patients were randomised to receive either risankizumab 150 mg or placebo at weeks 0, 4, and 16, followed by an open-label extension where all patients received risankizumab from week 24 onwards. Patients treated with risankizumab achieved higher response rates for resolution of enthesitis, dactylitis and both enthesitis/dactylitis manifestations compared with placebo at week 24, supporting risankizumab's role in managing PsA.